GlassScriptPhysician profile
Alendre Mcghee
NPI 1487978391
$1,957.76
in general payments reported to CMS, 2019-2025
11 companies · $591 in 2025
The $591 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $342 · 2023: $618 · 2024: $407 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613 · Education: $2.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,613.08 |
| Education | $2.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $483.01 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $435.72 | 2022-2025 | Spravato |
| Alkermes, INC. | $334.01 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Axsome Therapeutics, INC. | $204.73 | 2024-2025 | Auvelity, Sunosi, Symbravo |
| Novo Nordisk INC | $192.15 | 2025 | Ozempic, Wegovy, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $103.69 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $99.72 | 2023-2025 | Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.12 | 2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $27.18 | 2023-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $24.28 | 2025 | Hetlioz, Fanapt |
| Lilly USA, LLC | $16.15 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alendre Mcghee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.